In late January 2026, Axsome Therapeutics reported interim unaudited fourth-quarter 2025 results pointing to about US$196,000,000 in product revenue and roughly US$638,500,000 for full-year 2025, with ...

Axsome's current lineup features Auvelity, a medicine approved for depression; Sunosi, which treats daytime sleepiness ...

Axsome Therapeutics Inc. (NASDAQ:AXSM) ranks among the mid-cap stocks to buy according to top investors. On January 20, H.C.

Shares of Axsome Therapeutics (NASDAQ: AXSM) were sinking 6.8% lower as of 11:19 a.m. ET on Tuesday. The decline came after Culper Research announced a short position in the biotech stock before the ...

Axsome Therapeutics (AXSM) shares soared 4.1% in the last trading session to close at $184.5. The move was backed by solid ...

Axsome Therapeutics (NASDAQ:AXSM) has been analyzed by 11 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below summarizes their recent ...

Axsome Therapeutics Inc. (NASDAQ:AXSM) is one of the best mid-cap growth stocks to buy right now. On January 16, Piper ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $199.57, a high estimate of $260.00, and a low estimate of $154.00. Witnessing a positive shift, the current ...

Small-cap pharmaceutical stocks are in focus as late-stage trials and regulatory decisions approach, creating potential upside for investors.

Axsome Therapeutics AXSM is preparing to release its quarterly earnings on Monday, 2025-08-04. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect ...

Axsome Therapeutics, Inc. has three marketed CNS drugs and pipeline potential in Alzheimer's and narcolepsy. Read why AXSM stock is a buy.

Axsome Therapeutics AXSM announced the initiation of the phase III study called FORWARD with the dosing of the first patient, evaluating AXS-14 (esreboxetine) for the management of fibromyalgia.